As shown in a representative experiment involving 4 patients (Figure 4), NTZ-treated pDCs were less able to stimulate PPD-specific CD4+ T cell proliferation than non–NTZ-treated pDCs at the 3 time-points, which ranged from ∼54%–76% inhibition of the PPD response in 3 different experiments in NTZ-treated MS patients. Here, CD4 is linked to myeloid sarcoma.